US drugmaker Pfizer, which employs over 3,000 people in Ireland, has decided not to separate into two publicly traded companies by splitting its low-growth generics from its patent-protected branded medicines.
Instead, with the two operating as separate businesses within Pfizer, the company was already accessing many of the potential benefits of a split while retaining the operational strength, efficiency and financial flexibility of operating as a single company, chief executive Ian Read said.
“ Over time, any potential gap between Pfizer’s market valuation and an implied Sum of the Parts (SOTP) market valuation has closed,” said chief financial officer Frank D’Amelio.
“We concluded that splitting into two companies at this time would not enhance the cashflow generation and competitive positioning of the businesses and the operational disruption, increased costs of a split and inability to realise any incremental tax efficiencies would likely be value destructive.”
Pfizer’s shares were down 1.3 per cent in premarket trading on Monday.
Abandoned Irish deal
The company has for several years weighed whether a split made sense, largely because its patent-protected medicines routinely enjoy sales growth, while its portfolio of generics usually posted sales declines.
Investors shifted their focus to whether Pfizer would split after the company terminated a $160 billion (€142 bn) deal to acquire Irish drugmaker Allergan in April due to new tax inversion rules.
Pfizer said on Monday the decision not to split itself would not impact its 2016 forecast, and that it preserved the option to split in the future.
Pfizer in August announced it had agreed to buy cancer drugmaker Medivation Inc for $14 billion to gain access to blockbuster prostate cancer drug Xtandi for its growing oncology roster.
The Medivation deal illustrates a shift in Pfizer’s M&A strategy from lowering taxes – the rationale behind the failed Allergan tax inversion deal – to strengthening its lineup of branded drugs, especially lucrative cancer treatments.
A year ago, Pfizer paid $15 billion for Hospira, which sells generic hospital products and is developing biosimilars meant to compete with big-selling injectable biotech drugs. That deal was seen by Wall Street as a way of bolstering its generic drugs ahead of potentially divesting the business.
